Polythiazide: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Hypertension

Adult: 2-4 mg once daily.

Oral
Oedema

Adult: Initially, 1-4 mg once daily in the morning.

Contraindications

Hypersensitivity to sulfonamide-derived drugs, anuria.

Special Precautions

Patient w/ fluid and electrolyte imbalance, history of bronchial asthma, gout, DM. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation.

Adverse Reactions

Anorexia, gastric irritation, nausea, vomiting, cramping, diarrhoea, constipation, jaundice, pancreatitis, dizziness, vertigo, paraesthesias, headache, xanthopsia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anaemia, purpura, photosensitivity, rash, urticaria, necrotising angiitis, orthostatic hypotension, electrolyte imbalance, hyperglycaemia, glycosuria, hyperuricaemia, muscle spasm, weakness, restlessness.

Monitoring Parameters

Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Drug Interactions

May increase the risk of lithium toxicity. Hypokalaemia may develop w/ concomitant use of corticosteroids or ACTH. May augment the paralyzing actions of tubocurarine and decrease arterial responsiveness to norepinephrine. May alter antidiabetic dosing. Orthostatic hypotension may be aggravated w/ barbiturates or narcotics. Metabolic effects of hypokalaemia may be increased w/ concomitant digitalis therapy.

Lab Interference

May alter laboratory test results for K, BUN, glucose, and protein-bound iodine (PBI).

Action

Description: Polythiazide reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of Na and Cl ions and consequently of water. It also reduces the GFR.
Onset: Approx 2 hr.
Duration: 24-48 hr.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Distribution: Plasma protein binding: >80%.
Excretion: Via urine (as unchanged drug) and faeces. Elimination half-life: Approx 26 hr.

Storage

Store between 20-25°C.

MIMS Class

Diuretics

References

Buckingham R (ed). Polythiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/06/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Polythiazide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/06/2014.

Renese Tablet (Pfizer Labs). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/06/2014.

Disclaimer: This information is independently developed by MIMS based on Polythiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com